Skip to main content
Premium Trial:

Request an Annual Quote

Exonhit, Pfizer Collaborate on Alzheimer's Biomarkers

NEW YORK (GenomeWeb News) – Exonhit today announced a deal with Pfizer for use of Exonhit's technology for identifying biomarkers associated with Alzheimer's disease.

Exonhit's Genome-Wide SpliceArray platform will be used to identify progression and other biomarkers "that could segregate healthy elderly controls, patients with mild cognitive impairment … and patients with AD," the Paris-based company said.

Pfizer will provide samples from each of the three patient groups for the study.

Financial and other terms of the collaboration were not disclosed.

Exonhit's GWSA platform is a microarray-based technology that uses specific probe configuration to monitor RNA splice variants. It monitors known and predicted alternative RNA splicing events in about 21,000 human genes, Exonhit said.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.